The intrathecally administered kappa-2 opioid agonist GR89696 and interleukin-10 attenuate bone cancer-induced pain through synergistic interaction. [electronic resource]
Producer: 20120716Description: 934-40 p. digitalISSN:- 1526-7598
- Analgesics, Opioid -- administration & dosage
- Animals
- Anti-Inflammatory Agents -- administration & dosage
- Behavior, Animal -- drug effects
- Bone Neoplasms -- complications
- Breast Neoplasms -- pathology
- Cell Line, Tumor
- Disease Models, Animal
- Dose-Response Relationship, Drug
- Drug Synergism
- Female
- Injections, Spinal
- Interleukin-10 -- administration & dosage
- Pain -- drug therapy
- Pain Measurement
- Pain Threshold -- drug effects
- Piperazines -- administration & dosage
- Pyrrolidines -- administration & dosage
- Rats
- Rats, Sprague-Dawley
- Receptors, Opioid, kappa -- agonists
- Tibia -- pathology
- Time Factors
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.